Released: Monday 13th November 2023

Kelso Pharma initiates European expansion with acquisition of Italian specialty pharma company, Velit Biopharma

Kelso Pharma (Kelso), the growing UK-based specialty pharma business, has taken its first step in its European expansion strategy by agreeing to acquire Italian specialty pharma company, Velit Biopharma (Velit).

With more than 100 partnership agreements in place with pharma companies in Europe, Asia and the Middle East, Velit has a portfolio of more than 50 pharma products and a strong pipeline of additional medicines in development, with a number of products available to be commercialised in the UK through Kelso’s existing infrastructure.

Velit’s therapeutic focus includes: gastroenterology; dermatology; and women’s health, all of which are complementary to Kelso’s existing portfolio of medicines. In addition, Velit’s portfolio has products focusing on oncology and ophthalmology which, alongside Velit’s strong business development and regulatory teams, will further extend Kelso’s in-house capabilities.

Velit’s founder and President, Dr Nicola Travierso, is a well-known and respected figure in the international pharma community and will remain with the business and join Kelso’s executive management team. All other members of the Velit team will remain with the business, further building Kelso’s development, regulatory and business development capabilities. The transaction is conditional on receiving Italian regulatory clearance.

For more details please click here.